Table 1 Clinicopathologic features of SMARC-altered breast carcinomas.
Primary Class 1 SMARC Alterations (n = 11) | Primary Class 2 SMARC Alterations (n = 16) | P value, Fisher’s Exact Test | Metastatic Class 1 SMARC Alterations (n = 15) | Metastatic Class 2 SMARC Alterations (n = 15) | P value, Fisher’s Exact Test | |
|---|---|---|---|---|---|---|
Median age (range) | 52 (37–73) | 58.5 (37–80) | 50 (31–67) | 49.5 (34–76) | ||
Family history of breast cancer | (8/11, 73%) | (9/14, 64%) | 1.0 | (11/13, 87%) | (8/12, 67%) | 0.38 |
Germline BRCA1 or 2 | (2/8, 25%) | (3/9, 33%) | 1.0 | (1/10, 10%) | (1/9, 11%) | 1.0 |
Median tumor size (range) (cm) | 2.0 (0.8–4.6) | 1.6 (0.8–6.5) | ||||
Hormone receptors | ||||||
ER+HER2− | (4/11, 36%) | (10/16, 62%) | 0.25 | (7/15, 47%) | (10/15, 66%) | 0.46 |
ER−HER2− | (5/11, 45%) | (4/16, 25%) | 0.68 | (6/15, 40%) | (4/15, 27%) | 0.69 |
HER2+ | (2/11, 18%) | (2/16, 13%) | 1.0 | (2/15, 13%) | (1/15, 7%) | 1.0 |
Histology | ||||||
IDC-NST | (5/11, 45%) | (16/16, 100%) | <0.05 | (14/15, 93%) | (15/15, 100%) | 1.0 |
IDC with SMARC phenotype | (6/11, 55%) | (0/16, 100%) | (1/15, 7%) | (0/15, 0%) | 1.0 | |
Rhabdoid features | (3/11, 27%) | (1/15, 7%) | (0/15, 0%) | |||
Sarcomatoid features | (1/11, 9%) | |||||
Anaplastic features | (2/11, 18%) | |||||
Histologic grade | ||||||
2 | (1/11, 9%) | (4/16, 25%) | 0.62 | |||
3 | (10/11, 91%) | (12/16, 75%) | 0.62 | |||
SMARC protein expression | ||||||
Retained | (8/10, 80%) | (9/9, 100%) | 0.47 | (2/6, 33%) | (6/6, 100%) | 0.45 |
Lost | (1/10, 10%) | (0/9, 0%) | 1 | (0/6, 0%) | (0/6, 0%) | 1 |
Mosaic | (1/10, 10%) | (0/9, 0%) | 1 | (2/6, 33%) | (0/6, 0%) | 0.45 |
